← boardnext 2026-09
MAZE
Maze Therapeuticsdistress 4/10 · elevated risk$28.24-1%today-46% from 52w high
Lead: chronic kidney disease (CKD)
Revenue
$20M
Liquidity
$363M
Runway
3.0 yrs
Shares 1y
+26%
Price & events
-38.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.9%
1D
+4.0%
1W
+6.9%
1M
+8.6%
3M
-36.2%
6M
+60.1%
1Y
—
2Y
—
5Y
+77.1%
All
Overview
- Market Cap
- $1.56B
- Enterprise Value
- $1.40B
- Volume
- 25.22K
- 52 Week Range
- $13.14 – $51.84
- Total Shares
- 55.35M
- Float Shares
- 37.25M
- Short %
- 11.25%
- % Held by Insiders
- 1.46%
- % Held by Institutions
- 95.12%
- RVOL
- 0.03x
Pipeline stages · 1 programs
MZE829
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 2 | MZE829 | Proteinuric Kidney Disease | — | recruiting |
Catalyst news & presentations · 3
- second half of 2026Guided 55%trial initiationsecondaryPhase 2MZE782 · Initiate Phase 2 proof-of-concept trial evaluating proteinuria reduction in CKD.SEC 8-K
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-2026trial initiationsecondaryPhase 2MZE782 · Initiate Phase 2 proof-of-concept trial evaluating plasma phenylalanine reduction in PKU.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $63 (+121% upside) · 11 analysts
- 2026-04-14Truist SecuritiesBuy
- 2026-03-31JP MorganOverweight
- 2026-03-25BTIGBuy
- 2026-03-25HC Wainwright & Co.Buy
- 2026-03-18Truist SecuritiesBuy
- 2026-03-16WedbushOutperform
Competitors — chronic kidney disease (CKD)
- none identified
Recent news
- 2026-07-22Maze Therapeutics (MAZE) Investor presentation Summary - Quartr
- 2026-07-22Maze Therapeutics (MAZE) Q4 2025 earnings summary - Quartr
- 2026-07-21Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
- 2026-07-21Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect? - Zacks Investment Research
- 2026-07-14Maze Therapeutics Advances MZE782 Phase 2 PKU Trial, Setting Up a New Catalyst for MAZE Investors - TipRanks
- 2026-07-02Maze Therapeutics (NASDAQ: MAZE) R&D chief sells 14,609 shares near $30 - Stock Titan
- 2026-07-01Maze Therapeutics CSBO Atul Dandekar sells $210,150 in shares By Investing.com - Investing.com Canada
- 2026-06-29What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors? - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.